86 related articles for article (PubMed ID: 2440564)
41. Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization.
Chen K; Kuo SC; Hsieh MC; Mauger A; Lin CM; Hamel E; Lee KH
J Med Chem; 1997 Sep; 40(19):3049-56. PubMed ID: 9301667
[TBL] [Abstract][Full Text] [Related]
42. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent.
Jackson RC; Sebolt JS; Shillis JL; Leopold WR
Cancer Invest; 1990; 8(1):39-47. PubMed ID: 2190673
[No Abstract] [Full Text] [Related]
43. 2-(aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines, a new class of anticancer agents.
Capps DB; Dunbar J; Kesten SR; Shillis J; Werbel LM; Plowman J; Ward DL
J Med Chem; 1992 Dec; 35(26):4770-8. PubMed ID: 1479579
[TBL] [Abstract][Full Text] [Related]
44. [Acridines as antitumor drugs].
Dopierała A; Wrosz P; Mazerski J
Postepy Hig Med Dosw (Online); 2011 May; 65():263-9. PubMed ID: 21677347
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents.
Coronnello M; Ciciani G; Mini E; Guerrini G; Caciagli B; Selleri S; Costanzo A; Mazzei T
Anticancer Drugs; 2005 Jul; 16(6):645-51. PubMed ID: 15930893
[TBL] [Abstract][Full Text] [Related]
46. Current status of pyrazoloacridine as an anticancer agent.
Adjei AA
Invest New Drugs; 1999; 17(1):43-8. PubMed ID: 10555121
[TBL] [Abstract][Full Text] [Related]
47. Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).
Palomino E; Foster B; Kempff M; Corbett T; Wiegand R; Horwitz J; Baker L
Cancer Chemother Pharmacol; 1996; 38(5):453-8. PubMed ID: 8765439
[TBL] [Abstract][Full Text] [Related]
48. Diarylsulfonylureas--a new class of antitumor agents.
Guan X
IDrugs; 1998 Jul; 1(3):334-8. PubMed ID: 18465557
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study.
Berg SL; Blaney SM; Sullivan J; Bernstein M; Dubowy R; Harris MB;
J Pediatr Hematol Oncol; 2000; 22(6):506-9. PubMed ID: 11132217
[TBL] [Abstract][Full Text] [Related]
50. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro.
Aleskog A; Bashir-Hassan S; Hovstadius P; Kristensen J; Höglund M; Tholander B; Binderup L; Larsson R; Jonsson E
Anticancer Drugs; 2001 Nov; 12(10):821-7. PubMed ID: 11707649
[TBL] [Abstract][Full Text] [Related]
51. Immunoblot analysis and band depletion assays.
Kaufmann SH; Svingen PA
Methods Mol Biol; 1999; 94():253-68. PubMed ID: 12844881
[No Abstract] [Full Text] [Related]
52. Status of new anthrapyrazole and pyrazoloacridine derivatives.
Berg SL
Crit Rev Oncol Hematol; 1996 Mar; 22(2):79-87. PubMed ID: 8679102
[No Abstract] [Full Text] [Related]
53. Evaluation of Anticancer Activity of 1,3-Oxazol-4-ylphosphonium Salts in Vitro.
Brusnakov M; Golovchenko O; Velihina Y; Liavynets O; Zhirnov V; Brovarets V
ChemMedChem; 2022 Oct; 17(20):e202200319. PubMed ID: 36037305
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.
Ramaswamy B; Mrozek E; Kuebler JP; Bekaii-Saab T; Kraut EH
Invest New Drugs; 2011 Apr; 29(2):347-51. PubMed ID: 19844661
[TBL] [Abstract][Full Text] [Related]
55. The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.
Bridewell DJ; Porter AC; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 2008 Oct; 62(5):753-62. PubMed ID: 18175117
[TBL] [Abstract][Full Text] [Related]
56. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
57. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC
Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S
Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497
[TBL] [Abstract][Full Text] [Related]
59. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH
Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
